Oculis Holding AG Ordinary shares (OCS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.14 (+1.60%), Market cap $1.82B, 52-week low–high $16.13 ~ $32.65.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was for
Financial statements, price targets, institutional (13F) holdings and related news for Oculis Holding AG Ordinary shares are updated in real time on BlackAll Trade.
Oculis Holding AG Ordinary shares trades at $10.14 (+1.60%). Real-time quotes and charts are available on BlackAll Trade.
Oculis Holding AG Ordinary shares has a market cap of about $1.82B.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company